Answers are grounded in this paper and cite their sources.
Objective To describe the treatment and outcome for dogs with lower urinary tract carcinoma or prostatic carcinoma treated with intra-arterial vinblastine. Animals 14 client-owned dogs from a single private referral center identified through a search of the medical records as having either urothelial cell carcinoma (n = 8) or prostatic carcinoma (6) treated with intra-arterial vinblastine from September 1, 2016, through September 30, 2023. Clinical Presentation The most commonly reported clinical signs were pollakiuria, stranguria, and hematuria alone or in combination. Median duration of clinical signs prior to vinblastine treatment was 5 weeks (range, 1 to 18 weeks). Median body weight and age at intra-arterial vinblastine treatment were 14.85 kg (range, 5.7 to 33.5 kg) and 8 years (range, 6 to 11 years). There were 9 castrated males and 5 spayed females. Results Vinblastine was successfully administered via the internal iliac arteries in all cases. Clinical outcome was reported in 10 dogs: 9 improved, and 1 had stable clinical signs. Restaging was available for 8 dogs, of which 2 of 8 were classified as having partial response, 4 of 8 stable disease, and 2 of 8 progressive disease. Clinical Relevance Intra-arterial vinblastine was well tolerated in dogs in this study and may contribute to rapid clinical improvement. Intra-arterial vinblastine shows promise in treating urothelial cell carcinoma and prostatic carcinoma in dogs; however, additional research is needed.
No takes yet. Share an insight, caveat, or question.
Vigouroux et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: